Twist Bioscience (TWST) Q4 2025 Financial Results Summary

Twist Bioscience Corporation (TWST) Q4 2025 Financial Results Summary

Release Date: November 14, 2025

Twist Bioscience Corporation, a biotechnology company, reported its fourth quarter and full year financial results for fiscal year 2025, ending September 30, 2025. The results showed a significant increase in revenue with continued improvements in various operational metrics. Below is a summary of the key financial figures and highlights:

Fiscal 2025 Financial Results

• Total Revenue:
• Fiscal 2025 revenues reached $376.6 million, a 20% increase compared to $313.0 million in fiscal 2024.
• SynBio Revenue: Increased by 17%, totaling $145.0 million vs. $123.5 million in fiscal 2024.
• NGS Revenue: Increased by 23%, reaching $208.1 million compared to $169.1 million in fiscal 2024.

• Biopharma Revenue: Increased by 15% to $23.5 million from $20.3 million in the prior year.

• Cost of Revenues:

• Increased to $185.6 million in FY25 from $179.6 million in FY24.

• Gross Margin:

• Improved to 50.7%, an increase of 8.1 margin points from 42.6% in FY24.

• Research and Development Expenses:

• Decreased to $80.3 million from $90.9 million in FY24.

• Selling, General and Administrative Expenses:

• Increased to $247.0 million compared to $218.4 million from the previous year.

• Net Loss:

• The net loss attributable to common stockholders for FY25 was $77.7 million, or $1.30 per share, significantly reduced from $208.7 million, or $3.60 per share in fiscal 2024.

• Adjusted EBITDA:

• Adjusted EBITDA was $(46.9) million, improving from $(93.5) million in FY24.

• Cash Position:

• At the end of FY25, the company had $232.4 million in cash, cash equivalents, and short-term investments.

Fiscal 2025 Fourth Quarter Financial Results

• Total Revenue:
• Q4 FY25 revenues reached $99.0 million, a 17% increase compared to $84.7 million in Q4 FY24.
• SynBio Revenue: Increased by 17% to $39.5 million, compared to $33.9 million in the same quarter last year.
• NGS Revenue: Increased by 16% to $53.0 million, up from $45.5 million in Q4 FY24.

• Biopharma Revenue: Grew by 22%, totaling $6.4 million compared to $5.3 million in Q4 FY24.

• Cost of Revenues:

• Increased slightly to $48.2 million from $46.5 million in Q4 FY24.

• Gross Margin:

• Improved to 51.3% from 45.1% in Q4 FY24.

• Research and Development Expenses:

• Decreased to $17.0 million compared to $21.1 million in Q4 FY24.

• Selling, General and Administrative Expenses:

• Increased to $63.8 million from $53.1 million in Q4 FY24.

• Net Loss:

• The net loss attributable to common stockholders was $27.1 million, or $0.45 per share, down from $34.7 million, or $0.59 per share in Q4 FY24.

• Adjusted EBITDA:

• Adjusted EBITDA for Q4 FY25 was $(7.8) million, improving from $(17.0) million in Q4 FY24.

Recent Highlights

• Approximately 3,800 customers shipped products in FY25, an increase from approximately 3,550 in FY24.
• The company shipped around 938,000 genes in FY25, compared to 772,000 in FY24.
• Launched the Trinity Freestyle Fast Hybridization workflow for Element’s AVITI ™ sequencing platforms.
• Introduced the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel.
• Published a peer-reviewed paper in Science regarding nucleic acid biosecurity.
• Appointed Trynka Shineman to the Board of Directors.

Fiscal 2026 Financial Guidance

• For the full fiscal year 2026, Twist expects total revenue in the range of $425 million to $435 million, representing a growth of 13% to 15.5% year-over-year.
• For the first quarter of FY26, revenue is expected to be between $100 million and $101 million, reflecting growth of about 13% to 14% compared to Q1 FY25.
• Gross margin for FY26 is projected to be above 52%.

Note: No quarterly dividends or share repurchase announcements were made during this report.